DaVita Inc.

NYSE:DVA

Medical - Care Facilities

Healthcare
$161.79 +0.77%

+$1.60 today

Market cap
$10.18B
Beta
0.91
P/E (TTM)
18.2
EPS (TTM)
$11.60
52W Low $101.00High $213.44

Volume 1.12M

Average 0.84M

DVA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

DaVita Inc.NYSE: DVA

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $167.81M fell 3.9% year over year, behind the -0.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.

Context

  • Depreciation & amortization amounted to 5.2% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.9% toward the trailing-twelve-month pace of -0.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$167.81M-5.6% QoQ
Last fiscal yearDec 2025
$715.35M-1.2% YoY
LTMJun 2026
$709.83M-0.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year-1.2%——
3-year CAGR-0.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
715.35M USD
Year-over-year change
-1.2%
4-year CAGR
+1.3%

Depreciation & Amortization vs competitors

How DVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.3% is the highest of 3, against a peer median of -4.2%.
  • Depreciation & amortization amounts to 5.1% of revenue for DVA, versus a peer median of 8.2%.
DVA Competitors
Depreciation & Amortization for DVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€1.56B EUR-3.5%-6.5%8.0%
BAXBaxter International Inc.LTM Jun 2026$953M USD-5.0%-2.9%8.3%
DVADaVita Inc.LTM Jun 2026$709.83M USD-0.3%-0.8%5.1%
Peer median (excluding DVA) —-4.2%-4.7%8.2%

Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.21B781.64M691.54M1.25B1.08B
Depreciation & Amortization680.62M732.6M745.44M723.86M715.35M
Deferred Income Tax60.48M(75.67M)(39.35M)(57.84M)86.57M
Stock-Based Compensation102.21M95.43M112.38M102.79M139.95M
Change in Working Capital(140.64M)101K194.54M(29.82M)(263.24M)
Accounts Receivables(138.14M)(148.39M)172.36M(29.77M)(210.63M)
Inventory5.72M(757K)(32.13M)17.94M(19.95M)
Accounts Payables(30.32M)87.48M26.89M1.7M128.3M
Other Working Capital22.1M61.77M27.42M(19.7M)(160.96M)
Other Non-Cash Items16.45M30.47M354.5M32.31M129.15M
Operating Cash Flow1.93B1.56B2.06B2.02B1.89B
Capital Expenditures(641.47M)(603.43M)(567.99M)(555.44M)(575.86M)
Acquisitions (Net)(200.97M)(89.19M)(26.39M)(251.27M)(144.5M)
Purchases of Investments(33.84M)(133.39M)(322.95M)(24.46M)(22.44M)
Sales of Investments27.88M74.91M110M27.2M52.14M
Other Investing Activities63.66M120.76M35.52M32.54M35.71M
Investing Cash Flow(784.73M)(630.35M)(771.8M)(771.43M)(654.95M)
Debt Repayment754.26M(11.28M)(552.62M)1.11B769.62M
Common Stock Issued018.58M16.9M20.45M23.29M
Common Stock Repurchased(1.6B)(802.23M)(272.22M)(1.39B)(1.79B)
Dividends Paid00000
Other Financing Activities(238.59M)(326.2M)(362.56M)(560.56M)(374.69M)
Financing Cash Flow(1.08B)(1.12B)(1.17B)(816.94M)(1.37B)
Effect of Forex Changes(10.01M)(29.07M)8.91M(18.48M)21.15M
Net Change in Cash53.17M(215.97M)125.65M415.19M(122.08M)
Free Cash Flow1.29B961.14M1.49B1.47B1.31B

DaVita Inc.

NYSE:DVA

Intrinsic Alpha fair value

Locked

Current Price

$161.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.